International Edition
Latest News
Health

Blood Test Panels for HCC Surveillance Advance Through Clinical Evaluation

Biomarker panels designed to detect hepatocellular carcinoma are advancing through clinical evaluation, offering sensitivity rates that surpass traditional ultrasound methods in recent studies reported by CancerNetwork. The most heavily validated protein-based panels currently combine sex, age, alpha-fetoprotein, and…

Blood Test Panels for HCC Surveillance Advance Through Clinical Evaluation

Biomarker panels designed to detect hepatocellular carcinoma are advancing through clinical evaluation, offering sensitivity rates that surpass traditional ultrasound methods in recent studies reported by CancerNetwork.

The most heavily validated protein-based panels currently combine sex, age, alpha-fetoprotein, and des-gamma-carboxy prothrombin. These commercially available tests, known as the GALAD, GAAD, and ASAP panels, achieve sensitivity estimates in the mid-60 percent range alongside specificity ranging from the 70s to the low 80 percent range.

Researchers are also evaluating large-scale methylated DNA panels. Two prospective cross-sectional assessments showed sensitivity superior to ultrasound alone, though longitudinal cohort studies remain necessary to establish clinical utility and handle false-positive results.

Blood-based methylated DNA panels evaluated by Helio Genomics and Exact Sciences demonstrated higher sensitivity than ultrasound, with specificity estimates in the low 80 percent range. A case-controlled study presented at The Liver Meeting 2026 by Curve Biosciences evaluated a whole-body blood test showing early-stage sensitivity greater than 80 percent and very early-stage sensitivity exceeding 70 percent for lesions measuring 1 to 2 centimeters, maintaining a specificity of 81 to 82 percent.

“That is very promising performance in a case-control study, most notably the high sensitivity for very early-stage detection,” according to data published in October 2026 by CancerNetwork.

While these biomarker panels require further validation in cohort studies, they represent the closest researchers have come to developing a biomarker-only surveillance approach. Current surveillance relies primarily on ultrasound combined with alpha-fetoprotein testing.

Doctors rarely use hepatocellular carcinoma surveillance in practice. Systematic reviews indicate a pooled sensitivity of around 63 percent for ultrasound plus alpha-fetoprotein, while studies show that only one in four patients complete surveillance in the year before diagnosis.

Patients report logistical barriers such as transportation difficulties and uncertainty regarding radiology appointments separate from routine clinic visits. Providers similarly cite limited clinic time and competing demands as obstacles to coordinating separate imaging studies.

While interventions such as patient and provider education, radiology recall systems, and mailed outreach programs increase surveillance over short periods, multiyear adherence remains low due to the separation of imaging appointments from primary clinic visits.

Treatment patterns for liver cancer have shifted alongside changing etiologic factors, showing a decrease in viral hepatitis cases and increases in alcohol-associated liver disease and metabolic dysfunction-associated steatotic liver disease. Although improvements in surveillance utilization during the 2000s and late 2010s enhanced early detection, those gains receded during the COVID-19 pandemic and have not fully recovered.

Modern management increasingly incorporates sequential therapy, combination regimens, and neoadjuvant immunotherapy prior to surgical resection. Multidisciplinary care models, including co-located clinics and tumor boards, consistently demonstrate improved patient survival and increased delivery of curative therapies.

Exact Sciences, founded in 1995 and headquartered in Madison, Wisconsin, received FDA approval for its stool DNA test Cologuard in 2014, a milestone that triggered rapid growth and a series of acquisitions in blood-based screening.

The company purchased Thrive Earlier Detection Corp. and Base Genomics in 2020 to advance liquid biopsy technology, then collaborated with Helio Genomics on methylated DNA panels evaluated for hepatocellular carcinoma surveillance. Abbott Laboratories completed its roughly $21 billion acquisition of Exact Sciences in March 2026, making the firm a subsidiary.

To standardize North American treatment allocations, a multidisciplinary expert group published the BEACON-HCC treatment allocation system in the journal Hepatology on August 7, 2026. This system provides a structured starting point for determining appropriate interventions based on individual tumor burden.

About the author: Health Desk

Health Desk at Archynewsy.